Prophylactic Antiepileptic Treatment in Tuberous Sclerosis

Prerna Choudhury; Robert Spaull; Sam Amin; Andrew A Mallick; Jayesh S Patel; Finbar O'Callaghan; Andrew L Lux

doi:10.1016/j.pediatrneurol.2020.03.017

Prophylactic Antiepileptic Treatment in Tuberous Sclerosis

Prerna Choudhury, Robert Spaull, Sam Amin, Andrew A Mallick, Jayesh S Patel, Finbar O'Callaghan, Andrew L Lux^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter (Academic Journal) › peer-review

Abstract

Jóźwiak et al. suggest that their study, “…provides evidence that preventive antiepileptic treatment in infants with tuberous sclerosis complex improves long-term epilepsy control and cognitive outcome at school age.” The study is problematic, however, because it compares two groups that have been ascertained in entirely different ways: the “Standard” group after presentation with tuberous sclerosis complex and usually epilepsy and the “Preventive” group with suspected or proven tuberous sclerosis complex but without epilepsy.

Original language	English
Pages (from-to)	100-101
Number of pages	2
Journal	Pediatric Neurology
Volume	110
Early online date	5 Apr 2020
DOIs	https://doi.org/10.1016/j.pediatrneurol.2020.03.017
Publication status	Published - 1 Sep 2020

Bibliographical note

Acceptance date is provisional and based on date of publication.

Keywords

tuberous sclerosis complex
vigabatrin
antiepileptic drug treatment

Access to Document

10.1016/j.pediatrneurol.2020.03.017

Embargoed Document

Full-text PDF (author’s accepted manuscript)
Accepted author manuscript, 616 KB
Licence: CC BY-NC-ND
Embargo ends: 5/04/21
Request copy

Fingerprint Dive into the research topics of 'Prophylactic Antiepileptic Treatment in Tuberous Sclerosis'. Together they form a unique fingerprint.

Cite this

@article{9a8773a8000b43f79184e5c8182db5c2,

title = "Prophylactic Antiepileptic Treatment in Tuberous Sclerosis",

abstract = "J{\'o}{\'z}wiak et al. suggest that their study, “…provides evidence that preventive antiepileptic treatment in infants with tuberous sclerosis complex improves long-term epilepsy control and cognitive outcome at school age.” The study is problematic, however, because it compares two groups that have been ascertained in entirely different ways: the “Standard” group after presentation with tuberous sclerosis complex and usually epilepsy and the “Preventive” group with suspected or proven tuberous sclerosis complex but without epilepsy.",

keywords = "tuberous sclerosis complex, vigabatrin, antiepileptic drug treatment",

author = "Prerna Choudhury and Robert Spaull and Sam Amin and Mallick, {Andrew A} and Patel, {Jayesh S} and Finbar O'Callaghan and Lux, {Andrew L}",

note = "Acceptance date is provisional and based on date of publication.",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.pediatrneurol.2020.03.017",

language = "English",

volume = "110",

pages = "100--101",

journal = "Pediatric Neurology",

issn = "0887-8994",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Prophylactic Antiepileptic Treatment in Tuberous Sclerosis

AU - Choudhury, Prerna

AU - Spaull, Robert

AU - Amin, Sam

AU - Mallick, Andrew A

AU - Patel, Jayesh S

AU - O'Callaghan, Finbar

AU - Lux, Andrew L

N1 - Acceptance date is provisional and based on date of publication.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Jóźwiak et al. suggest that their study, “…provides evidence that preventive antiepileptic treatment in infants with tuberous sclerosis complex improves long-term epilepsy control and cognitive outcome at school age.” The study is problematic, however, because it compares two groups that have been ascertained in entirely different ways: the “Standard” group after presentation with tuberous sclerosis complex and usually epilepsy and the “Preventive” group with suspected or proven tuberous sclerosis complex but without epilepsy.

AB - Jóźwiak et al. suggest that their study, “…provides evidence that preventive antiepileptic treatment in infants with tuberous sclerosis complex improves long-term epilepsy control and cognitive outcome at school age.” The study is problematic, however, because it compares two groups that have been ascertained in entirely different ways: the “Standard” group after presentation with tuberous sclerosis complex and usually epilepsy and the “Preventive” group with suspected or proven tuberous sclerosis complex but without epilepsy.

KW - tuberous sclerosis complex

KW - vigabatrin

KW - antiepileptic drug treatment

U2 - 10.1016/j.pediatrneurol.2020.03.017

DO - 10.1016/j.pediatrneurol.2020.03.017

M3 - Letter (Academic Journal)

C2 - 32414624

VL - 110

SP - 100

EP - 101

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

ER -